Hillstream BioPharma Announces Pharmacokinetic Data of HSB-1216 Supportive of its Development Strategy and Pre-clinical Data
April 10 2023 - 8:47AM
Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the
"Company"), a biotechnology company developing a portfolio of
therapeutic candidates targeting drug resistant and devastating
cancers, announced pharmacokinetic (PK) data of HSB-1216 supportive
of its development strategy and pre-clinical data. These data
suggest Quatramer protects HSB-1216 from metabolic degradation
until its release at the tumor site and is consistent with the
promising efficacy data demonstrating effective reduction of tumor
growth in pre-clinical studies.
The preliminary safety and PK of HSB-1216 was evaluated in
IND-enabling studies using rats and dogs showing the Quatramer
bound HSB-1216 throughout a 48-hour exposure period prevented
degradation in the in systemic circulation until its targeted
release at the tumor site.
“We are greatly encouraged by these early PK data which are both
supportive of our overall development strategy as well as our
earlier pre-clinical data,” said Randy Milby, Hillstream’s Chief
Executive Officer.
About Hillstream BioPharma Inc.Hillstream
BioPharma, Inc. is a biotechnology company developing a portfolio
of therapeutic candidates targeting drug resistant and devastating
cancers. The Company anticipates submitting an investigational new
drug application in the second half of 2023 with HSB-1216, which
targets ferroptosis, an emerging new anti-cancer mechanism,
resulting in iron mediated cell death (IMCD) of drug resistant
cancers. The Company’s emerging immuno-oncology pipeline is led by
HSB-3215, a novel anti-HER2 monoclonal antibody targeting unique
epitopes with a novel mechanism of action. The erbB/HER family of
cell surface proteins include well-known and validated drug targets
including HER2 and HER3 found in multiple solid tumors, including
breast, lung, GYN, endocrine and CNS.
For more information, please visit: www.hillstreambio.com.
Forward Looking StatementsCertain statements in
this press release are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
may be identified using words such as “anticipate,” “believe,”
“forecast,” “estimated” and “intend” or other similar terms or
expressions that concern Hillstream’s expectations, strategy, plans
or intentions. These forward-looking statements are based on
Hillstream’s current expectations and actual results could differ
materially. There are several factors that could cause actual
events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not
limited to, clinical trials involve a lengthy and expensive process
with an uncertain outcome, and results of earlier studies and
trials may not be predictive of future trial results; our clinical
trials may be suspended or discontinued due to unexpected side
effects or other safety risks that could preclude approval of our
product candidates; risks related to business interruptions,
including the outbreak of COVID-19 coronavirus, which could
seriously harm our financial condition and increase our costs and
expenses; dependence on key personnel; substantial competition;
uncertainties of patent protection and litigation; dependence upon
third parties; and risks related to failure to obtain FDA
clearances or approvals and noncompliance with FDA regulations.
Investors should read the risk factors set forth in our Form 10-K
for the year ended December 31, 2022 and our periodic reports filed
with the Securities and Exchange Commission. While the list of
factors presented here is considered representative, no such list
should be considered to be a complete statement of all potential
risks and uncertainties. Unlisted factors may present significant
additional obstacles to the realization of forward-looking
statements. Forward-looking statements included herein are made as
of the date hereof, and Hillstream does not undertake any
obligation to update publicly such statements to reflect subsequent
events or circumstances.
Investor Relations
Contact:Email: investorrelations@hillstreambio.comwww.hillstreambio.com
Hillstream BioPharma (NASDAQ:HILS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hillstream BioPharma (NASDAQ:HILS)
Historical Stock Chart
From Apr 2023 to Apr 2024